America's medicine cabinet is too important to leave to the mercy of subsidized foreign suppliers and fragile supply chains. Lobbyists in Washington are at it again. They're warning of calamity if the Trump administration imposes Section 232 tariffs on imports of prescription generic drugs. They tell us that consumers will face higher prices.